A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Trial Profile

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs Gemcitabine (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Sponsors TARIS Biomedical
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 12 Jul 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top